Sarah Hardesty
Psychiatric/Mental Health · Louisville, KYNPI 1417618489
Payments from drug & device makers
Across 199 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$809
- Neurocrine Biosciences, Inc.$615
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$406
- E.r. Squibb & Sons, L.L.C.$381
- Alkermes, Inc.$377
- Teva Pharmaceuticals USA, Inc.$251
- plus $746 from 7 others
What the payments were for
- Food & beverage$3,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $809 |
| Neurocrine Biosciences, Inc. | 42 | $615 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $406 |
| E.r. Squibb & Sons, L.L.C. | 9 | $381 |
| Alkermes, Inc. | 21 | $377 |
| Teva Pharmaceuticals USA, Inc. | 14 | $251 |
| Vanda Pharmaceuticals Inc. | 9 | $234 |
| Johnson & Johnson | 9 | $200 |
| Otsuka America Pharmaceutical, Inc. | 6 | $123 |
| Lundbeck LLC | 4 | $85 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Indivior Inc. | 2 | $38 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,585 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 29 | $47,032 |
| Invega SustennaPaliperidone Palmitate | 17 | $45,010 |
| Lurasidone Hcl | 29 | $8,638 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 81 | $7,320 |
| Aripiprazole | 26 | $2,480 |
| Quetiapine Fumarate | 56 | $1,710 |
| Hydroxyzine Hcl | 32 | $1,121 |
| Atomoxetine Hcl | 12 | $1,072 |
| Oxcarbazepine | 16 | $964 |
| Duloxetine Hcl | 64 | $901 |
| Buspirone Hcl | 54 | $845 |
| Carbamazepine ErCarbamazepine | 13 | $487 |
| Amitriptyline Hcl | 16 | $460 |
| Mirtazapine | 38 | $392 |
| Sertraline Hcl | 51 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $809 | $47,03229 claims |
| Johnson & JohnsonInvega Sustenna | $200 | $45,01017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Louisville
- Denise de AngelisLouisville$384K
- Mark BushLouisville$52K
- Harold O'BrienLouisville$28K
- Shane WattsLouisville$13K
- Clinton RayhillLouisville$9K
- Michelle LoseLouisville$7K
- Ryan HopsonLouisville$7K
- Kimberly ViltLouisville$7K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.